About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...

Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat ...

The toll-free dial-in number for participants is 1 - 800 - 715 - 9871, conference ID: 1503863 . A webcast of the call will be accessible via Sienna's website. The webcast of the call will be available ...

Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key ...

Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4).

Verrica recognized collaboration revenue of $0.1 million for the three months ended September 30, 2024 related to the Collaboration and License Agreement (the “Torii Agreement”) with Torii ...

In addition, on November 4, 2024, Amwell made a grant of RSUs covering 5,084 shares of its Class A common stock to two new employees. The grants were offered as material inducement to the employees’ ...

Total revenues were $175.7 million in the third quarter of 2024, an increase of 14% compared to the same period in 2023. Total revenues excluding Trokendi XR ® and Oxtellar XR ® net product sales (non ...

Experience Empower 2024’s best moments here: https://www.inovalon.com/empower/.

Inspire is increasing its full year 2024 revenue guidance to between $793 million to $798 million, which represents growth of 27% to 28% over full year 2023 revenue of $624.8 million. This compares to ...

Strong balance sheet with cash, cash equivalents, and marketable securities of $267.4 million as of September 30, 2024, provides cash runway into 2027 CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) ...

COPENHAGEN, DENMARK and BOSTON, MA, USA, November 4, 2024 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has resolved, in accordance with the ...